The Center for Medicine in the Public Interest (CMPI) is a non-profit medical issues research group.[2] It was founded by the "free-market think tank" Pacific Research Institute.[3] CMPI's research agenda deals with clinical outcomes and econometric studies that analyze the value of new medicines and genomic and molecular-based medical innovation.
Abbreviation | CMPI |
---|---|
Typ | non-profit medical issues research group think tank |
Hauptsitz | New York City, United States |
Key people |
|
Revenue (2014) | $353,000[1] |
Expenses (2014) | $373,744[1] |
Website | cmpi.org |
CMPI is a 501(c)(3) organization and as such is not permitted to devote a substantial part of its activity to lobbying. Its officers have written articles on various issues including price controls on pharmaceutical products in publicly funded healthcare schemes in the United States,[4] and restrictions on advertising in the European Union.[5] The Economist Intelligence Unit has written that the organisation generally takes a pro-drug industry viewpoint.[6]
Issues
editUniversal healthcare
editCMMPI is a strong opponent of universal healthcare and favors a free-market approach to health care policy. The center created a website called BigGovHealth.org to tell the stories of people who faced difficulties with the health care systems in Europe and Canada. The site also included interviews with health policy experts in Europe and Canada. The website is no longer up, now showing a page where you can offer to purchase the domain.[7][8]
Drug imports
editThe group opposes the importation of drugs in order to lower prices in the United States, arguing in part that Canadian pharmaceutical companies' products are dangerous because they are not regulated by the FDA but by foreign government agencies.[9]
Personnel
editCMPI was founded by Peter Pitts, former FDA Associate Commissioner for External Relations under the Bush administration, and Dr. Robert Goldberg, former fellow at the Manhattan Institute.[10]
CMPI Senior Fellows include:
- Marc Siegel
- Doug Badger
- John F. P. Bridges
- Jacob Arfwedson
Finanzierung
editReports
editCMPI has published studies on the value of new cancer drugs, the cost-effectiveness of certain Alzheimer's treatments, evidence-based medicine, and drug counterfeiting.[12]
References
edit- ^ a b "Center for Medicine in the Public Interest" (PDF). Foundation Center. Retrieved 23 March 2017.
- ^ Herper, Matthew (2007-07-25). "The Nissen Doctrine". Forbes. Archived from the original on March 11, 2008. Retrieved 2008-01-14.
- ^ Lee Fang (Nov 18, 2009). "Exclusive: Attacks On Health Reform Orchestrated By Yet Another Shadowy Corporate Front Group — 'CMPI'". Center for American Progress. Retrieved 19 November 2009.
- ^ Goldberg, Robert (2006-12-25). "HillaryCare Comes Back". The Weekly Standard. News America Incorporated. Archived from the original on May 20, 2011. Retrieved 2008-01-14.
- ^ Pitts, Peter J. (2006-04-12). "Power to the Patients". The Wall Street Journal. Retrieved 2008-01-14.
- ^ "USA healthcare: FDA centenary prompts politicking". Economist Intelligence Unit. Economist Group. 2006-07-05. Retrieved 2008-01-14.
- ^ "Home". biggovhealth.com.
- ^ "Site attacks single-payer health care - POLITICO". Politico.
- ^ "Proposed drug importation bill would expose Americans to counterfeit meds". 23 January 2019.
- ^ Jason Lee Miller (2008-08-01). "Are Google Results Hazardous To Your Health?". WebProNews. iEntry, Inc. Archived from the original on 2008-01-12. Retrieved 2008-01-14.
- ^ "Site attacks single-payer health care - POLITICO". Politico.
- ^ Laurie Sullivan (2006-06-13). "Pharmaceuticals Slowly Adopting RFID To Protect Prescription Drug Supplies". Information Week. CMP Media LLC. Retrieved 2008-01-14.